The most important result of our work is that the protein concentration of ADAM17 in the tissue of both the CRC tumor and the surgical margin is higher in CRC patients with comorbidities such as DMT2 or CVD in comparison to CRC patients without these diseases. This evidence concerns the gene ADAM17 and colorectal carcinoma.